Black Diamond Therapeutics Inc
BDTX2.801USD
+0.211+8.15%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
158.75MMarktkapitalisierung
31.18KGV TTM
mehr Informationen über Black Diamond Therapeutics Inc Unternehmen
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.
Unternehmensinformationen
BörsenkürzelBDTX
Name des UnternehmensBlack Diamond Therapeutics Inc
IPO-datumJan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
AddresseOne Main Street, 14th Floor
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142
Telefon16174175868
Websitehttps://www.blackdiamondtherapeutics.com/
BörsenkürzelBDTX
IPO-datumJan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.89%
Venture Capital
18.81%
Investment Advisor/Hedge Fund
18.59%
Hedge Fund
7.37%
Research Firm
1.43%
Individual Investor
0.96%
Bank and Trust
0.18%
Pension Fund
0.02%
Other
15.76%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
254
48.67M
85.58%
-26.49M
2025Q1
261
50.38M
88.73%
-26.95M
2024Q4
246
57.08M
100.88%
-16.52M
2024Q3
250
57.38M
101.59%
-12.76M
2024Q2
242
55.35M
99.47%
-3.18M
2024Q1
244
48.01M
92.96%
-13.90M
2023Q4
235
47.28M
91.68%
-8.00M
2023Q3
256
45.71M
88.75%
-9.85M
2023Q2
259
50.33M
103.17%
+16.38M
2023Q1
277
29.49M
80.76%
-7.91M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
10.40M
18.29%
-67.48K
-0.64%
Mar 31, 2025
Versant Ventures
6.21M
10.92%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.60M
9.85%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
4.45M
7.82%
--
--
Apr 11, 2025
Bellevue Asset Management AG
2.73M
4.81%
-5.78M
-67.91%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.36M
4.15%
-47.11K
-1.96%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.14%
-57.11K
-2.37%
Mar 31, 2025
Tang Capital Management, LLC
2.07M
3.64%
--
--
Mar 31, 2025
Millennium Management LLC
1.10M
1.94%
+545.84K
+97.81%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Health Innovation Active ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Mehr Anzeigen
Fidelity Enhanced Small Cap ETF
Anteil0.04%
iShares Micro-Cap ETF
Anteil0.03%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
iShares Health Innovation Active ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
DFA Dimensional US Core Equity Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
